CVS Posts a Strong Quarter - Analyst Blog
November 03 2011 - 7:30AM
Zacks
CVS Caremark (CVS)
reported third quarter 2011 EPS of 65 cents, 8.3% up year over
year. However, after excluding the impact of certain one-time
items, adjusted EPS came in at 70 cents, surpassing the Zacks
Consensus Estimate of 67 cents and 9.3% higher than the year-ago
quarter adjusted EPS.
Net revenue increased 12.5% year
over year to $26.7 billion, almost in line with the Zacks Consensus
Estimate.
The Pharmacy Services segment
posted a robust 25.8% increase in revenues to $14.8 billion during
the reported quarter. The significant growth was primarily on the
back of the long-term contract with Aetna (AET) as
well as the acquisition of the Medicare Part D business of
Universal American Corp. (UAM).
These contracts, combined with an
increase in covered lives in the company’s existing Medicare Part D
business, also led to a 39.8% year-over-year rise in CVS’ pharmacy
network claims to 179.2 million. The Aetna contract also drove the
Mail Choice claims processed growth by 8.0% to 17.5 million.
Revenues from CVS’ Retail Pharmacy
increased 3.8% to $14.7 billion with same-store sales climbing
2.3%. While Pharmacy same-store sales rose 2.4%, front-end
same-store sales spiked 2.0%.
Pharmacy same-store sales witnessed
a 200 basis points (bps) drop due to recent generic introductions,
whereas the Maintenance Choice program had a positive impact of 140
bps on a net basis.
Gross margin during the quarter
contracted 175 bps to 19.4% primarily due to 14.9% rise in cost of
revenues. Operating margin declined 30 bps to 5.9%.
CVS exited the third quarter, 2011
with cash and cash equivalents of $1.7 billion, up from $1.4
billion at the end of fiscal 2010. The company’s continuous share
buyback program benefited the bottom line. Year to date, the
company returned over $3 billion to its shareholders in the form
dividends and share repurchases.
During the third quarter, CVS
opened 39 new retail drugstores, closed 1 retail drugstore.
Additionally, the company relocated 14 retail drugstores. At the
end of the third quarter, CVS operated 7,384 locations, including
7,304 retail drugstores, 31 retail specialty pharmacy stores, 32
apothecary pharmacy stores, 13 specialty mail order pharmacies and
4 mail order pharmacies in 44 states, the District of Columbia and
Puerto Rico.
Guidance
Based on a solid quarter, CVS
narrowed down its EPS outlook for fiscal 2011. The company now
expects adjusted EPS of $2.77–$2.81 (earlier guidance being
$2.75–$2.81). The current Zacks Consensus Estimate of $2.78 is
within this range. The guidance for cash flow from operations and
free cash flow for fiscal 2011, however, remained unchanged at
$5.5–$5.6 billion and $4.0–$4.2 billion, respectively.
Our
Recommendation
We are encouraged by the improved
performance of CVS’ Pharmacy Services segment for the third
consecutive quarter, which had earlier been a drag on the company’s
performance. We are also encouraged by CVS’ several recent contract
wins over Medco (MHS) in the recent past, which
include Federal Employee Program (FEP) contract in May 2011, as
well as the biggest US public pension fund Calpers.
We are confident about CVS
Caremark’s longer-term potential based on its retail execution,
deployment potential and the strong 2012 generics cycle. However,
the proposed merger between Express Script (ESRX)
and Medco will intensify competition in the Pharmacy Services
segment.
CVS currently retains a short-term
Zacks#3 (Hold) Rank, which also reflects our ‘Neutral’
recommendation over the long term.
AETNA INC-NEW (AET): Free Stock Analysis Report
CVS CAREMARK CP (CVS): Free Stock Analysis Report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
MEDCO HLTH SOL (MHS): Free Stock Analysis Report
UNIVL AMERICAN (UAM): Free Stock Analysis Report
Zacks Investment Research
Medco (NYSE:MHS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medco (NYSE:MHS)
Historical Stock Chart
From Jul 2023 to Jul 2024